- Home
- PMTS vs CCCC Comparison
PMTS vs CCCC Comparison
Compare PMTS & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMTS
- CCCC
- Stock Information
- Founded
- PMTS 2007
- CCCC 2015
- Country
- PMTS United States
- CCCC United States
- Employees
- PMTS N/A
- CCCC N/A
- Industry
- PMTS Finance Companies
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- PMTS Finance
- CCCC Health Care
- Exchange
- PMTS Nasdaq
- CCCC Nasdaq
- Market Cap
- PMTS 327.9M
- CCCC 104.4M
- IPO Year
- PMTS 2015
- CCCC 2020
- Fundamental
- Price
- PMTS $24.30
- CCCC $1.52
- Analyst Decision
- PMTS Strong Buy
- CCCC Buy
- Analyst Count
- PMTS 4
- CCCC 3
- Target Price
- PMTS $36.75
- CCCC $12.00
- AVG Volume (30 Days)
- PMTS 52.4K
- CCCC 1.4M
- Earning Date
- PMTS 08-04-2025
- CCCC 07-31-2025
- Dividend Yield
- PMTS N/A
- CCCC N/A
- EPS Growth
- PMTS 1.33
- CCCC N/A
- EPS
- PMTS 1.58
- CCCC N/A
- Revenue
- PMTS $491,426,000.00
- CCCC $39,783,000.00
- Revenue This Year
- PMTS $14.61
- CCCC N/A
- Revenue Next Year
- PMTS $12.49
- CCCC N/A
- P/E Ratio
- PMTS $15.95
- CCCC N/A
- Revenue Growth
- PMTS 12.81
- CCCC 98.56
- 52 Week Low
- PMTS $18.46
- CCCC $1.09
- 52 Week High
- PMTS $35.19
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- PMTS 57.79
- CCCC 51.15
- Support Level
- PMTS $22.88
- CCCC $1.36
- Resistance Level
- PMTS $24.04
- CCCC $1.56
- Average True Range (ATR)
- PMTS 0.68
- CCCC 0.12
- MACD
- PMTS 0.23
- CCCC -0.00
- Stochastic Oscillator
- PMTS 59.15
- CCCC 42.11
About PMTS CPI Card Group Inc.
CPI Card Group Inc is a payment technology company engaged in providing financial payment card solutions and services. It offers credit, debit, and prepaid cards. The business segments of the group are Debit and Credit, which produces Financial Payment Cards and provides integrated card services to card-issuing banks in the United States, and Prepaid Debit, which provides integrated card services to Prepaid Debit Card program managers in the United States and Others. It derives key revenue from the Debit and Credit segment.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.